Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 2, 2012, Pages 132-144

  Zhou, Aiping ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Adverse event management; Renal cell carcinoma; Sunitinib

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIARRHEAL AGENT; AXITINIB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CODEINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IMATINIB; LEVOTHYROXINE; LIDOCAINE; LOPERAMIDE; MORPHINE; NIFEDIPINE; NITRATE; PAZOPANIB; PREGABALIN; SORAFENIB; SUNITINIB; VERAPAMIL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; BLOOD CLOTTING DISORDER; BODY SURFACE; BONE MARROW SUPPRESSION; BRAIN DISEASE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HAIR COLOR; HAND FOOT SYNDROME; HEALTH CARE PERSONNEL; HEART FAILURE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; INTERVENTION STUDY; JAUNDICE; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYOCARDIAL DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; PAIN; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES;

EID: 84860240623     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01525.x     Document Type: Review

References (53)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Naito S, Tomita Y, Rha SY etal. Kidney cancer working group report. Jpn J Clin Oncol 2010; 40 (Suppl.): i51-56.
3. Motzer RJ, Hutson TE, Tomczak P etal. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-90.
4. Gore M, Szczylik C, Porta C etal. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009; 10: 757-63.
5. Cella D, Li JZ, Cappelleri JC etal. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol 2008; 26: 3763-9.
6. Houk BE, Bello CL, Poland B etal. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 357-71.
7. Lee S, Mainwaring P, Ng C etal. An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma. Eur J Cancer Suppl 2009; 7: 428.
8. Kim H, Hong M, Shin SJ etal. Sunitinib for unselected Korean patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles [Abstract]. J Clin Oncol 2010; 28 (Suppl.): e15107.
9. Yoo C, Kim JE, Lee JL etal. The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction. Jpn J Clin Oncol 2010; 40: 980-5.
10. Hong MH, Kim HS, Kim C etal. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 2009; 41: 67-72.
11. Hwang E, Lee HJ, Sul CK, Lim JS. Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience. Korean J Urol 2010; 51: 450-5.
12. Li XS, Song Y, Gong K etal. Clinical study of sunitinib in the treatment of metastatic renal clear cell carcinoma: a single center 23 cases experience. Chin J Surg 2010; 48: 375-7.
13. Hu XY, Wang GU, Guo GM etal. Preliminary clinical study results of sunitinib in patients with metastatic renal cell carcinoma. Chin J Urol 2010; 31: 300-3.
14. Zeng SL, Zeng H, Xiang L etal. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma. Chin J Urol 2010; 31: 304-7.
15. Uemura H, Shinohara N, Yuasa T etal. A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol 2010; 40: 194-202.
16. Tomita Y, Shinohara N, Yuasa T etal. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 2010; 40: 1166-72.
17. Motzer RJ, Hutson TE, Tomczak P etal. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24.
18. Houk BE, Bello CL, Kang D etal. A population pharmacokinetic meta-analysis of sunitinib malate (su11248) and its primary metabolite (su12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009; 15: 2497-506.
19. Barrios CH, Hernandez-Barajas D, Brown MP etal. Clinical outcome of Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC) with continuous once-daily dosing of sunitinib as first-line therapy [Abstract]. Ann Oncol 2010; 21 (Suppl. 8): 913P.
20. Motzer RJ, Michaelson MD, Rosenberg J etal. Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007; 178: 1883-7.
21. Motzer RJ, Hutson TE, Olsen MR etal. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial [Abstract]. J Clin Oncol 2011; 29 (Suppl. 7): LBA308.
22. Choueiri TK, Xie W, Kollmannsberger CK etal. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration [Abstract]. J Clin Oncol 2010; 28: 4524.
23. van der Veldt AA, Boven E, Helgason HH etal. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008; 99: 259-65.
24. Ge J, Chen Y, Yang L etal. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: Potential risk of diminished sunitinib bioavailability. J Mol Med 2011; 89: 595-602.
25. Sunitinib package insert. [cited 11 Dec 2010]. Available from:
26. Lacouture ME, Wu S, Robert C etal. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-11.
27. National Cancer Institute (NCI). Common terminology criteria for adverse events (CTCAE): version 4.0. [updated 14 June 2010 cited 23 January 2012]. Available at:
28. Lammie A, Drobnjak M, Gerald W etal. Expression of c-Kit and Kit ligand proteins in normal human tissues. J Histochem Cytochem 1994; 42: 1417-25.
29. Faivre S, Delbaldo C, Vera K etal. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
30. Robert C, Soria JC, Spatz A etal. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500.
31. Thompson DS, Greco FA, Spigel DR etal. Bevacizumab, erlotinib, and imatinib in the treatment of patients with advanced renal cell carcinoma: update of a multicenter phase II trial. J Clin Oncol 2006; 24 (Suppl. 18S): 4594.
32. Maitland ML, Bakris GL, Black HR etal. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102: 596-604.
33. Kollmannsberger C, Soulieres D, Wong R etal. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1 (2 Suppl.): S41-54.
34. Singh RB, Suh IL, Singh VP etal. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens 2000; 14: 749-63.
35. Wolf-Maier K, Cooper RS, Kramer H etal. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-7.
36. Wolf-Maier K, Cooper RS, Banegas JR etal. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9.
37. Izzedine H, Ederhy S, Goldwasser F etal. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20: 807-15.
38. Miura S, Fujino M, Matsuo Y etal. Nifedipine induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res 2005; 28: 147-53.
39. Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010; 36: 416-24.
40. Izzedine H, Massard C, Spano JP etal. VEGF signaling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46: 439-48.
41. Orphanos GS, Ioannidis GN, Ardavanis AG. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 2009; 48: 964-70.
42. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 2009; 20 (Suppl 1): i7-12.
43. Kumar R, Crouthamel MC, Rominger DH etal. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101: 1717-23.
44. Wolter P, Stefan C, Decallonne B etal. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer 2008; 99: 448-54.
45. Mannavola D, Coco P, Vannucchi P etal. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92: 3531-4.
46. Wong E, Rosen LS, Mulay M etal. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007; 17: 351-5.
47. Rini BI, Tamaskar I, Shaheen P etal. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81-3.
48. Sato S, Muraishi K, Tani J etal. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocr J 2010; 57: 873-80.
49. Riesenbeck LM, Bierer S, Hoffmeister I etal. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 2010; 29: 807-13.
50. Bello CL, Garrett M, Sherman L etal. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol 2010; 66: 699-707.
51. Rini BI, Cohen DP, Lu D etal. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib [Abstract]. ASCO 2010; [abstract 312 ).
52. Bono P, Rautiola J, Utriainen T, Joensuu H. Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma. Acta Oncol 2011; 50: 569-73.
53. Kollmannsberger C Bjarnason G, Burnett P etal. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 2011; 16: 543-53.